Seeking Alpha

Merck & Co Inc. (MRK)

  • Dec. 11, 2012, 10:48 AM
    Cardiome Pharma (CRME +41%) leaps higher out of an earlier trading halt after the company says it's reached a deal with Merck (MRK +0.6%) to settle its debt obligations stemming from it's collaboration on vernakalant - a treatment for atrial fibrillation - which it signed in April 2009. Under the terms of the settlement, CRME will pay MRK $20M to settle its outstanding debt of $50M, and MRK will terminate a $100M credit facility it had made available to CRME.
    | Comment!
  • Dec. 11, 2012, 8:53 AM
    India revokes yet another pharmaceutical patent owned by a foreign multinational, with Merck (MRK) losing protection for an asthma treatment after domestic drug-maker Cipla challenged an earlier decision. Pfizer, Roche and Novartis are among those to have experienced patent trouble in the country. (previous)
    | 1 Comment
  • Dec. 9, 2012, 2:27 AM
    The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)
    | 1 Comment
  • Dec. 7, 2012, 4:41 AM
    The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA).
    | Comment!
  • Dec. 4, 2012, 8:13 AM
    An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court.
  • Dec. 3, 2012, 2:13 PM
    Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces. The drug attempts to prevent a worsening of Alzheimer's by blocking production of a protein believed to contribute to the disease. Eli Lilly (LLY) has reported positive Phase III trial results for its solanezumab Alzheimer's drug, when administered to patients with mild symptoms.
    | Comment!
  • Nov. 28, 2012, 5:56 AM
    Numerous CEOs of major companies are off to Washington today to talk to President Obama and/or John Boehner about averting the fiscal cliff. Those meeting Obama include the leaders of Merck (MRK), Coca-Cola (KO) and Caterpillar (CAT), while those meeting Boehner include the CEOs of Honeywell (HON) and Aetna (AET). Company bosses have also been urging their staff to pressure Washington to reach a deal.
  • Nov. 27, 2012, 3:29 PM
    Merck (MRK) declares $0.43/share quarterly dividend, 2.38% increase from prior dividend of $0.42. Forward yield 3.89%. For shareholders of record Dec 17. Payable Jan 08. Ex-div date Dec 13. (PR)
    | Comment!
  • Nov. 27, 2012, 10:16 AM
    Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR)
    | 1 Comment
  • Nov. 15, 2012, 5:56 PM
    Johnson & Johnson (JNJ), Merck (MRK) and Eli Lilly (LLY) are collaborating in a global project to create a database aimed at getting patient tests of experimental drugs up and running more quickly and efficiently, which would eventually mean new medicines will get approved and reach patients sooner. The database will give drug companies working on experimental drugs a one-time approval process and drug makers a big pool of ready, qualified scientists with known expertise.
    | Comment!
  • Nov. 14, 2012, 6:15 PM
    Diabetes is running at record levels worldwide, with half of the people estimated to have it not even diagnosed yet, according to the International Diabetes Federation. Poorer countries are where it's spreading most rapidly, with four out of five diabetics now living in low and middle-income countries. Inevitably, the market for diabetes drugs is exploding along with it - now expected to be around $48B - $53B by 2016.
  • Nov. 13, 2012, 9:02 AM
    Merck's (MRK) Stromectol treatment, which is usually used against parasitic worms, is also rather handy at killing bed bugs. Emergency physician John Sheele tested the pill on himself and three colleagues, finding that it killed three out of five bugs when taken three hours before the blood suckers started feasting.
    | Comment!
  • Nov. 12, 2012, 2:20 PM
    Bristol Myers (BMY -0.6%) is lower today after being cut to Market Perform at BMO Capital on the back of strong competitive Hep-C data from competitor Gilead (GILD +11.5%) and Merck's (MRK +0.3%) anti-PD-1 cancer immunotherpy results.
    | Comment!
  • Nov. 12, 2012, 8:17 AM
    Merck's (MRK +1.1%) MK-3475 treatment performed well in a Phase IB study of 85 patients with advanced melanoma, with 43 experiencing an "objective response." Of those, eight had a "complete response." Merck now plans to start Phase II trials of MK-3475. The drug is part of a new class of agents called PD-1 inhibitors, which help the immune system to overcome tumors. (PR)
    | Comment!
  • Nov. 11, 2012, 3:19 AM
    Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective in Phase II trials. A regimen that included Merck's MK-5172 suppressed the virus in most patients and appears to be better than the company's Victrelis. Merck now intends to conduct new studies, while Abbott has already started Phase III trials of a regimen of three of its treatments - ABT-450, boosting agent ritonavir (ABT-267) and ABT-333.
    | Comment!
  • Nov. 5, 2012, 5:53 PM
    Citi is out with its latest investment screen selecting U.S.-based dividend-paying stocks of companies that also earn approval in the credit markets. Three newcomers make the list - MRK, PFE, PGN - plus a dozen holdovers: MO, AEP, T, BMY, COP, ED, D, DUK, LLY, LMT, SO, VZ.
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.